Affinia Therapeutics
Affinia Therapeutics focuses on adeno-associated virus (AAV) gene therapy, aiming to positively impact lives affected by severe diseases using their proprietary ART platform.
Company Overview
Affinia Therapeutics specializes in adeno-associated virus (AAV) gene therapy. The company's aim is to create a lasting positive impact on the lives of individuals affected by devastating diseases. Affinia Therapeutics uses a proprietary platform called ART, which stands for Affinia Rationally-designed Therapies. This platform is designed to help develop new gene therapies for various medical conditions.
Focus Areas
Affinia Therapeutics concentrates its efforts on both rare and prevalent diseases impacting the nervous system, neuro-oncology, muscle, and lung. The company is dedicated to advancing gene therapy that targets these areas to develop effective treatments for patients suffering from a range of serious conditions.
Proprietary Platform: ART
At the core of Affinia Therapeutics' approach is ART, which stands for Affinia Rationally-designed Therapies. This proprietary platform is used to develop a new generation of AAVs. These engineered AAVs are intended to improve the delivery and efficacy of gene therapies and to address logistical challenges in the field of gene therapy.
Innovation in AAV Development
Affinia Therapeutics develops extensive libraries of AAVs to broaden the possibilities of gene therapy. The company focuses on creating novel cardiotropic and BBB-penetrant AAV capsids, aiming to improve preclinical efficacy and safety in conditions such as genetic cardiomyopathies and sporadic ALS. These advancements were presented at notable events like the American Society of Gene & Cell Therapy 2024 Annual meeting.
Conference Presentations
Affinia Therapeutics has presented significant preclinical data at reputable conferences, including the 30th European Society of Gene and Cell Therapy 2023 Annual Congress. The data highlighted novel AAV capsids and their potential in various therapeutic applications. Such presentations underscore the company's commitment to transparency and innovation in the field of gene therapy.